Stephen Helliwell

Stephen Helliwell currently serves as Chief Scientific Officer at cellvie and acts as an Expert for Innosuisse. Previously, Stephen held various roles including Member of the Board of Directors at rejuveron telomere therapeutics, Rejuveron Vascular Therapeutics AG, and Rejuveron Senescence Therapeutics, as well as serving as a Board Observer at Rejuvenate Biomed. With extensive experience at Novartis, Stephen contributed significantly as a Senior Investigator in multiple projects focused on liver disease and mitochondrial dysfunction. Academic credentials include a PhD in Biochemistry from the University of Basel and a BSc in Biochemistry from the University of Kent.